Ligand efficiency and fragment-based drug discovery.

Area of Science:

• Drug discovery and medicinal chemistry
• Computational chemistry
• Biochemistry

Background:

• Fragment-based drug discovery (FBDD) is increasingly utilized for developing optimized, low molecular weight compounds.
• Ligand efficiency (LE) is a key metric for evaluating fragments and drug candidates.
• LE is size-dependent, limiting its utility for comparing molecules of different molecular weights.

Purpose of the Study:

• To introduce a novel, size-independent efficiency score called fit quality.
• To assess the effectiveness of LE and fit quality in evaluating FBDD optimization.
• To compare the performance of LE and fit quality using literature-derived FBDD examples.

Main Methods:

• Literature review of fragment-based drug discovery (FBDD) case studies.
• Calculation and comparison of Ligand Efficiency (LE) for various molecular structures.
• Calculation and comparison of the novel fit quality score for assessing ligand optimization.

Main Results:

• Starting fragments in FBDD generally exhibit higher LE than larger, optimized structures.
• The novel fit quality score demonstrates improvement upon fragment optimization.
• Fit quality offers a size-independent assessment of ligand efficiency.

Conclusions:

• Fit quality provides a more reliable measure of ligand optimization in FBDD compared to LE.
• The developed fit quality score addresses the limitations of LE in assessing compounds of differing molecular weights.
• This metric aids in the rational design and optimization of drug candidates within FBDD workflows.